News
-
-
PRESS RELEASE
PolyPeptide Group: Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.
Samsung Biologics provides provisional interim result of public tender offer for PolyPeptide Group AG, with 87.92% participation rate and 87.59% tendered shares. Offer conditions met; details at samsungbiologics.com/offer -
-
-
-
PRESS RELEASE
Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by FDA
Formycon and Zydus announce FDA review of FYB206, first publicly announced Keytruda biosimilar filing, marking regulatory milestone under licensing agreement with Zydus. Could accelerate access to cancer therapy for patients -
-
-
-